

Sheet 1 of 17

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2026-4230US1SERIAL NO.
09/155,590

INFORMATION DISCLOSURE CITATION

*(Use several sheets if necessary)*APPLICANT(S)
Jeffrey Schlom et alFILING DATE
September 30, 1998GROUP ART UNIT
1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
HAC	2,253,211	2/9/92	GB	—	—		
HAC	WO 89/06974	8/10/89	WO	—	—		

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Papers, Etc.)*

HAC	HAC	Rotzschke, O. et al, Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells, <u>Nature</u> 1990, 348:252-254.
		Skipper, J. et al, Identification of Two Cytotoxic T Lymphocyte-recognized Epitopes in the Ras Protein, <u>The Journal of Experimental Medicine</u> , 177 (5), 1993, 1493-1498.

EXAMINER

Hope Robinson Eudelt

DATE CONSIDERED

3/21/90 15/5/90

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 17

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2026-4230US1SERIAL NO.
09/155,590

INFORMATION DISCLOSURE CITATION

*(Use several sheets if necessary)*APPLICANT(S)
Jeffrey Schlom et alFILING DATE
September 30, 1998GROUP ART UNIT
1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Papers, Etc.)*

		Abrams, S.I. et al, Mutant <i>ras</i> epitopes as targets for cancer vaccines, <u>Sem. Oncol.</u> 23, 118-134 (1996).
		Eishenlohr, L.C. et al, A transient transfection system for identifying biocynthesized proteins processed and presented to class I MHC restricted T lymphocytes, <u>J. Immunol. Meth.</u> , 1992, 154:131.

EXAMINER

DATE CONSIDERED

3/21/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 3 of 17

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2026-4230US1SERIAL NO.
09/155,590

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT(S)
Jeffrey Schlom et alFILING DATE
September 30, 1998GROUP ART UNIT
1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

AR		Peace, D.J. et al, T cell recognition of transforming proteins encoded by mutated <i>ras</i> proto-oncogenes, <u>J. Immunol.</u> , 146, 2059-2065, (1991).
AR		Takahashi, H.S. et al, A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp 160, <u>Science</u> , 1989, Vol. 246, 118-121.

EXAMINER

Hope Robinson Eubank

DATE CONSIDERED

3/22/99 10/5/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 4 of 17

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2026-4230US1SERIAL NO.
09/155,590

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT(S)
Jeffrey Schlom et alFILING DATE
September 30, 1998GROUP ART UNIT
1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)


		Rock, K.L. et al, Analysis of the association of peptides of optimal length to class I molecules or the surface of cells, <u>Proc. Natl. Acad. Sci. USA</u> 1992, Vol. 89, 8918-8922.
		Mitsudomi, T. et al, P53 mutation in non small lung cancer cell line and their correlation with the presence of <i>ras</i> mutations and clinical features, <u>Oncogene</u> 1992, Vol. 7, No. 1, 171-180.

EXAMINER

DATE CONSIDERED

3/24/00 10/5/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 2026-4230US1	SERIAL NO. 09/155,590
	APPLICANT(S) Jeffrey Schlom et al		
	FILED DATE September 30, 1998		GROUP ART UNIT 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILED DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

		Kahn, S.M. et al, Rapid and sensitive nonradioactive detection of mutant K-ras genes via enriched PCR amplification, <u>Oncogene</u> , Vol. 6, No. 6, 1079-1083 (1991).
		Fenton, R.G. et al, Cytotoxic T-Cell Response and In Vivo Protection Against Tumor Cells Harboring Activated ras Proto-oncogenes, <u>Journal of the National Cancer Institute</u> , Vol. 85, No. 16, August 18, 1993.

EXAMINER 	DATE CONSIDERED 3/21/00 10/5/00
---------------------	---

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. 2026-4230US1	SERIAL NO. 09/155,590
	APPLICANT(S) Jeffrey Schlom et al	
	FILING DATE September 30, 1998	GROUP ART UNIT 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

		Tsang, K.Y. et al, Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine, <u>J. Natl. Cancer Inst.</u> , Vol. 87, No. 13, July 1995, 982-990.
		Hamer, P.J. et al, Activated Val-12 ras p21 in cell culture fluids and mouse plasma, <u>Oncogene</u> , Vol. 6, No. 9, 1609-1615 (1991).

EXAMINER**DATE CONSIDERED**

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2026-4230US1SERIAL NO.
09/155,590

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT(S)
Jeffrey Schlom et alFILING DATE
September 30, 1998GROUP ART UNIT
1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

HAR		Carter, G. et al, <i>Ras</i> mutations in patients following cytotoxic therapy for lymphoma, <i>Oncogene</i> , Vol. 5, No. 3, 1990, 411-416.
		Fenton, R.G. et al, Induction of T-Cell Immunity Against <i>Ras</i> Oncoproteins by Soluble Protein or <i>Ras</i> -Expressing <i>Escherichia coli</i> , <i>Journal of the National Cancer Institute</i> (Bethesda), Vol. 87, No. 24, 1995, 1853-1861.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2026-4230US1SERIAL NO.
09/155,5904

INFORMATION DISCLOSURE CITATION

*(Use several sheets if necessary)*APPLICANT(S)
Jeffrey Schlom et alFILING DATE
September 30, 1996GROUP ART UNIT
1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Papers, Etc.)*


HR		Capon, D. J. et al, Activation of Ki-ras 2 gene in human colon and lung carcinomas by two different point mutations, <u>Nature</u> , Vol. 304, No. 11, August 1983, 507-513.
HR		Bos, J.L., The ras gene family and human carcinogenesis, <u>Mutation Research</u> , 195 (1988), 255-271.

EXAMINER

Hope Johnson Eudet

DATE CONSIDERED

*3/21/90 105/8***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2026-4230US1SERIAL NO.
09/155,5904

INFORMATION DISCLOSURE CITATION

*(Use several sheets if necessary)*APPLICANT(S)
Jeffrey Schlom et alFILING DATE
September 30, 1996GROUP ART UNIT
1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Papers, Etc.)*

HAR		Van Bleek, G. et al, Isolation of an endogenously processed immunodominant viral peptide from the class I H-2K molecule, <u>Nature</u> 1990, 348:213-216.
		Mitsudomi, T. et al, <i>Ras</i> gene mutation in non small lung cancer are associated with shortened survival irrespective of treatment intent, <u>Cancer Research</u> 1991, 51:4999-5002.

EXAMINER

DATE CONSIDERED

3/21/00 015/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2026-4230US1SERIAL NO.
09/155,590**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*APPLICANT(S)
Jeffrey Schlom et alFILING DATE
September 30, 1996GROUP ART UNIT
1643**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE


FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

		Bos, J.L., <i>ras</i> Oncogenes in Human Cancer: A Review, <u>Cancer Research</u> 49, 4682-4689 (1989).
		Fossum, B. et al, CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21- <i>Ras</i> -derived peptide (GLY ¹³ >ASP), are cytotoxic towards a carcinoma-cell line harbouring the same mutation, <u>Cancer Immunol. Immunotherapy</u> 40, 165-162 (1995).

EXAMINER



DATE CONSIDERED

3/21/00 10/5/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2026-4230US1SERIAL NO.
09/155,590**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*APPLICANT(S)
Jeffrey Schlom et alFILING DATE
September 30, 1996GROUP ART UNIT
1643**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

		Qin, H. et al, CD4+ T-cell immunity to mutated <i>ras</i> protein in pancreatic and colon cancer patients, <u>Cancer Research</u> 55, 2984-2987 (1995).
		Abrams, S.I. et al, Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K- <i>ras</i> p21, <u>Eur. J. Immunol.</u> 25, 2588-2597 (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2026-4230US1SERIAL NO.
09/155,5904

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT(S)
Jeffrey Schlom et alFILING DATE
September 30, 1996GROUP ART UNIT
1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

HAR		Abrams, S.I. et al, Identification of overlapping epitopes in mutant <i>ras</i> oncogene peptides that activate CD4+ and CD8+ T cell responses, <u>Eur. Journal of Immunology</u> 26 (2) 1996, 435-443.
HAR		Gjertsen, M.K. et al, <i>Ex vivo ras</i> peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study, <u>Int. J. Cancer</u> 65, 450-453 (1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2026-4230US1SERIAL NO.
09/155,590**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*APPLICANT(S)
Jeffrey Schlom et alFILING DATE
September 30, 1996GROUP ART UNIT
1643**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)


HAC		Van Elsas, A. et al, Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21 <i>Ras</i> peptided presented by HLA-A *0201, <u>Int. J. Cancer</u> 61, 389-396 (1995).
HAC		Kiaris, H. et al, Mutations of <i>ras</i> genes in human tumours (review), <u>Int. J. Oncol.</u> 7, 413-421 (1995).

EXAMINER

Hope Robinson Eud

DATE CONSIDERED

*3/21/00 10/5/00***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. 2026-4230US1	SERIAL NO. 09/155,590
	APPLICANT(S) Jeffrey Schlom et al	
	FILING DATE September 30, 1996	GROUP ART UNIT 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

HAR		Fossum, B. et al, Overlapping epitopes encompassing a point mutation (12 Gly > Arg) in p21
		ras can be recognized by HLA-DR, -DP and -DQ restricted T cells, <u>Eur. J. Immunol.</u> 23, 2687-2691 (1993).
HAR		Geddle-Dahl III et al, T-cell responses against products of oncogenes: generation and
		characterization of human T-cell clones specific for p21 Ras-derived synthetic peptides, <u>Human Immunol.</u> 33, 266-274 (1992).

EXAMINER


Hope Peterson Eudett

DATE CONSIDERED

5/21/90 10/5/90

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. 2026-4230US1	SERIAL NO. 09/155,590
	APPLICANT(S) Jeffrey Schlom et al	
	FILING DATE September 30, 1996	GROUP ART UNIT 1643



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

		Salter, R.D. et al, Impaired assembly and transport of HLA-A and B antigens in a mutant TxB hybrid, <u>EMBO J.</u> , 5, 943-949 (1986).
		Jung, S. et al, Human T lymphocytes recognize a peptide of single point-mutated, oncogenic <i>ras</i> proteins, <u>J. Exp. Med.</u> , 163, 273-276 (1991).

EXAMINER 	DATE CONSIDERED
---------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. 2026-4230US1	SERIAL NO. 09/155,590
	APPLICANT(S) Jeffrey Schlom et al	
	FILING DATE September 30, 1996	GROUP ART UNIT 1643

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

HAC		Khleif, S.N. et al, Induction of T cell responses after vaccination with specific <i>Ras</i> mutant peptides in cancer patients, <u>Proceedings of the American Association for Cancer Research</u> , Vol. 37, March 1996, Abstract.
HAR		Tsang, K.Y. et al, Induction of Human Cytotoxic T Cell Lines Directed Against Point-Mutated p21 Ras-Derived Synthetic Peptides, <u>Vaccine Research</u> , Vol. 3, No. 4, p. 183-193, 1994.

EXAMINER <i>Hope Robinson</i>	DATE CONSIDERED <i>3/21/00 145/00</i>
---	---

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2026-4230US1SERIAL NO.
09/155,590

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)APPLICANT(S)
Jeffrey Schlom et alFILING DATE
September 30, 1996GROUP ART UNIT
1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Papers, Etc.)*

HAR		Gaudernack, G., T cell responses against mutant <i>ras</i> , a basis for novel cancer vaccines
		<u>Immunotechnology 2</u> (1996), pp. 3-9.
HAR		Carbone et al, Feasibility of immunization with individualized mutant <i>ras</i> and p53 peptides
		in patients with solid tumors, <u>Proc. ASCO</u> Vol. 14, p. 546 (6/14/95).
EXAMINER	HAR Robinson Eudt	
	DATE CONSIDERED 3/21/00 10/5/00	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.